The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells

  • Authors:
    • Hyun-Sook Kim
    • Kwang Sik Suh
    • Donggeun Sul
    • Byung-Jo Kim
    • Seung Kwan Lee
    • Woon-Won Jung
  • View Affiliations

  • Published online on: October 31, 2011     https://doi.org/10.3892/ijmm.2011.822
  • Pages: 169-177
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteoblastic bone formation and osteoclastic bone resorption are in balance to maintain a constant, homeostatically controlled amount of bone. Excessive bone resorption by osteoclasts is involved in the pathogenesis of bone-related disorders. In the present study, we evaluated the inhibitory effects of glabridin, a flavonoid purified from licorice root, on the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation and its molecular mechanisms in murine osteoclast progenitor RAW264.7 cells. Glabridin significantly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity, the formation of multinucleated osteoclasts and resorption-pit formation. In mechanistic studies of the anti-osteoclastogenic potential of glabridin, we found that glabridin inhibited RANKL-induced expression of c-Fos and subsequent expression of NFATc1, which is a master regulator of osteoclastogenesis. Interestingly, glabridin inhibited the RANKL-induced expression of signaling molecules (TRAF6, GAB2, ERK2, JNK1 and MKK7) and osteoclast survival-related signaling pathways such as c-Src, PI3K and Akt2. Glabridin also inhibited the bone resorptive activity of mature osteoclasts by inhibiting osteoclast-associated genes (cathepsin K, MMP-9, CAII, TCIRG1, OSTM1 and CLCN7). Taken together, our data suggest that glabridin holds great promise for use in preventing osteoclastogenesis by inhibiting RANKL-induced activation of signaling molecules and subsequent transcription factors in osteoclast precursors and these findings may be useful for evaluating treatment options in bone-destructive diseases.

Related Articles

Journal Cover

February 2012
Volume 29 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim H, Suh KS, Sul D, Kim B, Lee SK and Jung W: The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells. Int J Mol Med 29: 169-177, 2012.
APA
Kim, H., Suh, K.S., Sul, D., Kim, B., Lee, S.K., & Jung, W. (2012). The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells. International Journal of Molecular Medicine, 29, 169-177. https://doi.org/10.3892/ijmm.2011.822
MLA
Kim, H., Suh, K. S., Sul, D., Kim, B., Lee, S. K., Jung, W."The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells". International Journal of Molecular Medicine 29.2 (2012): 169-177.
Chicago
Kim, H., Suh, K. S., Sul, D., Kim, B., Lee, S. K., Jung, W."The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells". International Journal of Molecular Medicine 29, no. 2 (2012): 169-177. https://doi.org/10.3892/ijmm.2011.822